Clinical bottom line
Emerging therapies aimed at activating brown adipose tissue (BAT) represent a promising but still investigational approach to improving metabolic health in obesity and type 2 diabetes (T2D). BAT activation enhances energy expenditure and glucose metabolism in preclinical models and early-phase human studies, suggesting potential benefits for weight reduction and glycemic control. However, clinical evidence remains limited, with small sample sizes and short durations. Current data do not yet support routine clinical use of BAT-targeting agents, but ongoing trials may clarify their role as adjuncts to established therapies.
What the evidence shows
Brown adipose tissue is specialized in thermogenesis, dissipating energy as heat via uncoupling protein 1 (UCP1). Its activation increases energy expenditure and glucose uptake, making it a putative target for obesity and T2D management. Human BAT activity declines with age and obesity, but can be stimulated by cold exposure, pharmacologic agents, and possibly dietary components.
Several classes of emerging agents have been investigated:
- **β3-adrenergic receptor (β3-AR) agonists:** These mimic sympathetic stimulation of BAT. Mirabegron, a β3-AR agonist approved for overactive bladder, increased resting energy expenditure and improved insulin sensitivity in small trials of adults with obesity or T2D (Cypess et al., 2015; PMCID: PMC4580672). However, cardiovascular side effects and variable BAT recruitment limit its current clinical use.
- **Thyroid hormone analogs and mimetics:** Thyroid hormones regulate BAT thermogenesis. Selective thyroid hormone receptor β agonists have shown promise in preclinical models to enhance BAT activity and improve lipid and glucose metabolism without systemic thyrotoxicosis (Grover et al., 2020; PMID: 32059718). Clinical data remain preliminary.
- **Fibroblast growth factor 21 (FGF21) analogs:** FGF21 is a metabolic hormone that induces browning of white adipose tissue and stimulates BAT. Clinical trials of FGF21 analogs demonstrated modest improvements in insulin sensitivity and lipid profiles in T2D and obesity, though effects on BAT activation per se were not directly measured (Gaich et al., 2013; PMID: 23706672).
- **Capsaicin and dietary compounds:** Capsaicin and related compounds can activate transient receptor potential channels, promoting BAT thermogenesis. Small studies suggest potential modest metabolic benefits, but robust clinical trials are lacking (Yoneshiro et al., 2017; PMID: 28223420).
Overall, systematic reviews highlight that while BAT activation is a compelling mechanistic target, clinical trials have been limited by small cohorts, short follow-up, and heterogeneous endpoints (Ouellet et al., 2021; PMID: 33446894).
Caveats and uncertainty
- **Population heterogeneity:** BAT volume and activity vary widely by age, sex, ethnicity, and adiposity, complicating generalizability.
- **Measurement challenges:** BAT activity assessment relies on PET-CT or MRI, which are costly and not standardized for routine clinical use.
- **Safety concerns:** β3-AR agonists can have off-target cardiovascular effects; long-term safety data are lacking.
- **Magnitude of effect:** Current interventions produce modest increases in energy expenditure insufficient alone for meaningful weight loss or glycemic improvement.
- **Lack of large-scale RCTs:** Definitive evidence from adequately powered randomized controlled trials assessing clinical outcomes is absent.
How this may change practice
At present, BAT-targeting therapies remain investigational and should not replace established obesity and T2D treatments. Clinicians should be aware of ongoing research and emerging agents in development, as these may complement lifestyle and pharmacologic interventions in the future. Understanding BAT biology may also inform personalized approaches to metabolic disease management, particularly in patients with residual BAT activity. Referral to clinical trials may be appropriate for interested patients. Meanwhile, optimizing evidence-based therapies remains paramount.